RBC Capital raised the firm’s price target on Design Therapeutics (DSGN) to $5 from $4 and keeps a Sector Perform rating on the shares. The company has now entered the clinic with both of its key programs and remains on track for data updates in the first half on Fuchs, and potentially mid-year on successful SAD – single-ascending dose – to MAD – multiple ascending dose – progression for Friedreich’s ataxia, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue